Want to see VYNE full AI Analyst Report?
Top Page
VYNE Therapeutics
(NASDAQ:VYNE)
Select Model
Select Model
Rating:51Neutral
Price Target:
$0.68
▲(16.38% Upside)
Action:Reiterated
Date:07/10/26
The score is held back primarily by weak financial performance—minimal/declining revenue, persistent large losses, and ongoing cash burn—partly offset by low debt and constructive near-term corporate events around the Yarrow merger and contingent special dividend. Technicals are mildly positive but not strong enough to outweigh the fundamental deficits, while valuation remains difficult to support due to negative earnings.
Positive Factors
Very low leverage / minimal debt
Minimal debt materially reduces interest and refinancing risk, preserving strategic optionality while the company executes R&D and potential M&A. With ongoing cash burn, a low-debt base buys time for financing or partnership solutions without immediate solvency stress.
Negative Factors
Persistent negative free cash flow
Sustained negative free cash flow forces recurrent financing or dilutive transactions, constraining long-term flexibility. Continued cash burn relative to negligible revenues limits the company’s ability to self-fund development, increasing execution and dilution risk absent partner funding or successful asset monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / minimal debt
Minimal debt materially reduces interest and refinancing risk, preserving strategic optionality while the company executes R&D and potential M&A. With ongoing cash burn, a low-debt base buys time for financing or partnership solutions without immediate solvency stress.
Read all positive factors
VYNE Therapeutics (VYNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.29M
Dividend YieldN/A
Average Volume (3M)2.75M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth-24.96%
EPS Growth46.11%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding33,385,056
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap-0.66
Enterprise Value/Revenue-31.09
Enterprise Value/Gross Profit-31.50
Enterprise Value/Ebitda0.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
VYNE Therapeutics Business Overview & Revenue Model
Company Description
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finishe...
How the Company Makes Money
As a clinical-stage company, VYNE Therapeutics does not have publicly disclosed, recurring product-sales revenue from commercialized drugs (null). Its cash inflows have primarily been driven by financing activities such as issuing equity and, wher...
VYNE Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 454.00K | 570.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| Gross Profit | 448.00K | 547.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| EBITDA | -21.69M | -26.73M | -39.80M | -27.87M | -33.86M | -38.04M |
| Net Income | -21.46M | -26.48M | -39.83M | -28.45M | -23.21M | -73.33M |
Balance Sheet | ||||||
| Total Assets | 25.87M | 30.16M | 66.91M | 97.69M | 40.76M | 67.05M |
| Cash, Cash Equivalents and Short-Term Investments | 24.93M | 29.01M | 61.52M | 93.25M | 30.91M | 42.25M |
| Total Debt | 0.00 | 0.00 | 99.00K | 214.00K | 0.00 | 349.00K |
| Total Liabilities | 1.24M | 2.40M | 14.82M | 8.95M | 9.56M | 18.41M |
| Stockholders Equity | 24.64M | 27.77M | 52.09M | 88.73M | 31.20M | 48.64M |
Cash Flow | ||||||
| Free Cash Flow | -25.74M | -33.12M | -34.09M | -25.34M | -29.20M | -56.37M |
| Operating Cash Flow | -25.74M | -33.12M | -33.97M | -25.34M | -29.20M | -56.37M |
| Investing Cash Flow | 22.24M | 37.37M | 23.36M | -57.35M | 15.67M | 1.03M |
| Financing Cash Flow | -71.00K | -143.00K | -141.00K | 82.39M | 1.65M | 39.78M |
VYNE Therapeutics Technical Analysis
Positive
0.58
Price Trends
0.66
Negative
0.63
Positive
0.54
Positive
Market Momentum
<0.01
Negative
50.98
Neutral
52.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Positive. The current price of 0.58 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.66, and above the 200-day MA of 0.54, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.98 is Neutral, neither overbought nor oversold. The STOCH value of 52.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VYNE.
VYNE Therapeutics Risk Analysis
VYNE Therapeutics disclosed 85 risk factors in its most recent earnings report. VYNE Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VYNE Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $21.29M | -1.36 | -74.15% | ― | -24.96% | 46.11% | |
50 Neutral | $13.10M | ― | -96.39% | ― | ― | 80.68% | |
49 Neutral | $6.27M | -2.29 | -60.33% | ― | 23.52% | 48.34% | |
45 Neutral | $153.72M | -1.90 | -116.86% | ― | -98.25% | 76.83% | |
42 Neutral | $21.84M | -0.38 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
VYNE
VYNE Therapeutics
0.71
-0.58
-44.88%
KZIA
Kazia Therapeutics
13.47
2.67
24.72%
XBIO
Xenetic Biosciences
3.00
-0.74
-19.79%
KALA
KALA BIO
0.96
-272.79
-99.65%
INAB
IN8bio
1.38
-0.79
-36.26%
VYNE Therapeutics Corporate Events
Business Operations and StrategyDividendsM&A TransactionsShareholder Meetings
VYNE declares special dividend ahead of Yarrow merger
Positive
Jul 10, 2026
On July 10, 2026, VYNE Therapeutics announced that its board had declared a special cash dividend estimated at $16.5 million, or about $0.38 per share, tied to its previously disclosed merger with Yarrow Bioscience under a December 17, 2025 Merger...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline
Positive
May 21, 2026
On May 21, 2026, Yarrow Bioscience published an investor presentation outlining its strategy and clinical plans, which VYNE Therapeutics in turn made available via its investor website as part of broader disclosure tied to their proposed reverse m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.